Orexo AB (STO: ORX) (OTCQX: ORXOY), a Sweden-based pharmaceutical company, announced on Tuesday that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for review of OX124.
OX124 is a nasal rescue medication for opioid overdose containing a high dose of naloxone and is the first product based on Orexo´s drug delivery platform, amorphOX. The Prescription Drug User Fee Act (PDUFA) date is set to 15 July 2024, but recent review processes in the category indicate a risk of some delay.
OX124 is a potent medication and, in combination with rapid absorption and high bioavailability, this makes it capable of reversing an overdose or sustaining consciousness in a patient who has taken synthetic opioids.
It is an innovative powder-based technology that improves stability and reduces sensitivity related to temperature changes in addition to rapid absorption and high bioavailability.
Pierre Fabre Pharmaceuticals reports FDA acceptance and Priority Review of Tabelecleucel BLA
Bavarian Nordic's chikungunya vaccine receives validation from EMA for accelerated review
Atara Biotherapeutics gains FDA Priority Review for tabelecleucel
Hyperfine secures FDA clearance for faster brain imaging software
Silo Pharma agrees Alzheimer's drug licence
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation
Camurus reports positive Phase 3 ACROINNOVA 2 results
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI